Interleukin Genetics, Inc.

Other

Sitokine Limited

Cardioforecast Ltd.

Crawford Healthcare Holdings Limited

Gordon W Duff

Kenneth S Kornman

Francesco Saverio Di Giovine

Lynn Doucette-Stamm

David C Crossman

Sheila E Francis

Simon Van Dijk

Peter John Barnes

Nicola Jane Camp

Katherine Stephenson

Angela Cox

Samson Lim

John Rogus

Simon Ward

Ian G Rennie

Katherine Martinez

Patrick R S Richardson

Martin Nicklin

Paul Martha

Srdjan Vitovski

Claes Bavik

Jon R Sayers

Paul M Martha, Jr

Franco Di Giovine

Michael Cork

Richard Eastell

Graham Russell

Steven Offenbacher

Leon Wilkins

Rachid Tazi-Ahnini

Hong Min Chen

Francesco Saverio De Giovine

The present invention relates to methods and kits for treating cardiovascular disease.

Methods and kits for treating cardiovascular disease

The present invention provides stratification methods and kits to identify whether an individual having an inflammation-related disorder has genotype-specific differential expression of IL-1, i.e., is a 'high' or 'low' producer of IL-1, such that s/he can be provided an appropriate anti-inflammatory drug and at an appropriate dose. The stratification of high or low IL-1 producers is used to guide assignment of different drug doses and therefore reduce drug toxicity and adverse events in an individual who, without stratification, may be prescribed a higher dose than needed to manage the primary indication. The use of IL-1 stratification of drug dosing would allow a better clinical benefit-risk appraisal in an individual patient.

Methods for predicting response to treatment

The present invention relates, in part, to methods and kits for treating cardiovascular disease.

The kits and methods of the present invention relate to the diagnosis of cardiovascular disorders. In one aspect, the invention discloses a method and a kit for determining whether a subject has a fragile plaque disorder. In one aspect, the invention discloses a method and a kit for determining whether the subject has an occlusive disorder. In one aspect, the invention discloses a method and a kit for determining whether the subject has a restenosis disorder. Other methods of the present invention relate to the selection of therapeutics for a patient with a cardiovascular disease.

Method for diagnosing myocardial infarction

Diagnostics and therapeutics for osteoporosis, which are bases upon the identification of a subjects IL-1 haplotype and genotype pattern are described.

Diagnostics and therapeutics for osteoporosis

Methods and kits for detecting polymorphisms that are predictive of a subject's susceptibility to developing an obstructive airway disease, such as asthma, as well as for determining the relative severity of the disease are described. Assays for identify therapeutics are also described.

Diagnostics and therapeutics for an obstructive airway disease

Methods, assays and kits are disclosed for detecting a mother's or a fetus's susceptibility to an adverse pregnancy outcome such as low birth weight. The methods comprise obtaining a biological sample from a patient and determining the presence or absence of an IL-1 allele 2 of a marker that is associated with an adverse pregnancy outcome.

Fetal testing for prediction of low birth weight

A method of predicting whether a subject is predisposed to developing early-onset menopause is provided. The method involves genotyping a patient at the IL-1 gene loci.

Methods of diagnosing early-onset menopause

Methods and kits for determining whether a subject has or is predisposed to developing restenosis are provide.

Diagnostics and therapeutics for restenosis

A method and kit for predicting increased risk of sight-threatening diabetic retinopathy which includes isolating genomic DNA from a sample from a diabetic patient. The genetic polymorphism pattern for the genes IL-1A, IL-1B and IL-1RN is then identified in the DNA. The identified pattern is compared with control patterns of known polymorphisms, and patients expressing a genetic polymorphism pattern associated with increased risk of sight-threatening diabetic retinopathy are identified.

Detecting genetic predisposition to sight-threatening diabetic retinopathy

Methods and kits for determining whether a subject has or is predisposed to developing a disease which is associated with IL-1 polymorphisms and assays for identifying therapeutics for treating and/or preventing the development of these diseases are provided.

Diagnostics and therapeutics for diseases associated with an IL-1 inflammatory haplotype

Diagnostics and therapeutics for osteoporosis, which are based on the identification of the subject's IL-1 haplotype pattern are described.

Methods and kits for detecting polymorphism that are predictive of a subject's susceptibility to developing sepsis are described.

Growing community of inventors

Sheffield, United Kingdom

Gordon W Duff